These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 25329977)
1. Influence of search parameters and criteria on compound selection, promiscuity, and pan assay interference characteristics. Hu Y; Bajorath J J Chem Inf Model; 2014 Nov; 54(11):3056-66. PubMed ID: 25329977 [TBL] [Abstract][Full Text] [Related]
2. Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurement-dependent compound promiscuity. Hu Y; Bajorath J J Chem Inf Model; 2012 Oct; 52(10):2550-8. PubMed ID: 22978710 [TBL] [Abstract][Full Text] [Related]
3. Compound promiscuity: what can we learn from current data? Hu Y; Bajorath J Drug Discov Today; 2013 Jul; 18(13-14):644-50. PubMed ID: 23524195 [TBL] [Abstract][Full Text] [Related]
5. Compound Data Mining for Drug Discovery. Bajorath J Methods Mol Biol; 2017; 1526():247-256. PubMed ID: 27896746 [TBL] [Abstract][Full Text] [Related]
6. Identification of orthologous target pairs with shared active compounds and comparison of organism-specific activity patterns. Dimova D; Stumpfe D; Bajorath J Chem Biol Drug Des; 2015 Nov; 86(5):1105-14. PubMed ID: 25931211 [TBL] [Abstract][Full Text] [Related]
7. Systematic assessment of compound series with SAR transfer potential. Zhang B; Wassermann AM; Vogt M; Bajorath J J Chem Inf Model; 2012 Dec; 52(12):3138-43. PubMed ID: 23186159 [TBL] [Abstract][Full Text] [Related]
8. Evolution of the activity cliff concept for structure-activity relationship analysis and drug discovery. Bajorath J Future Med Chem; 2014 Sep; 6(14):1545-9. PubMed ID: 25367389 [No Abstract] [Full Text] [Related]
9. Analyzing Promiscuity at the Level of Active Compounds and Targets. Bajorath J Mol Inform; 2016 Dec; 35(11-12):583-587. PubMed ID: 27870240 [TBL] [Abstract][Full Text] [Related]
10. From activity cliffs to activity ridges: informative data structures for SAR analysis. Vogt M; Huang Y; Bajorath J J Chem Inf Model; 2011 Aug; 51(8):1848-56. PubMed ID: 21761918 [TBL] [Abstract][Full Text] [Related]
11. Biodiversity of small molecules--a new perspective in screening set selection. Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345 [TBL] [Abstract][Full Text] [Related]
12. Monitoring global growth of activity cliff information over time and assessing activity cliff frequencies and distributions. Stumpfe D; Bajorath J Future Med Chem; 2015 Aug; 7(12):1565-79. PubMed ID: 26334207 [TBL] [Abstract][Full Text] [Related]
14. Enhancing Molecular Promiscuity Evaluation Through Assay Profiles. Avram S; Curpan R; Bora A; Neanu C; Halip L Pharm Res; 2018 Oct; 35(11):240. PubMed ID: 30338400 [TBL] [Abstract][Full Text] [Related]
15. Compound optimization through data set-dependent chemical transformations. de la Vega de León A; Bajorath J J Chem Inf Model; 2013 Jun; 53(6):1263-71. PubMed ID: 23654345 [TBL] [Abstract][Full Text] [Related]
16. A data mining method to facilitate SAR transfer. Wassermann AM; Bajorath J J Chem Inf Model; 2011 Aug; 51(8):1857-66. PubMed ID: 21774471 [TBL] [Abstract][Full Text] [Related]
17. Analyzing compound activity records and promiscuity degrees in light of publication statistics. Hu Y; Bajorath J F1000Res; 2016; 5():. PubMed ID: 27347396 [TBL] [Abstract][Full Text] [Related]
18. Report and Application of a Tool Compound Data Set. Butler KV; MacDonald IA; Hathaway NA; Jin J J Chem Inf Model; 2017 Nov; 57(11):2699-2706. PubMed ID: 29035535 [TBL] [Abstract][Full Text] [Related]
19. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493 [TBL] [Abstract][Full Text] [Related]
20. Scientific competency questions as the basis for semantically enriched open pharmacological space development. Azzaoui K; Jacoby E; Senger S; Rodríguez EC; Loza M; Zdrazil B; Pinto M; Williams AJ; de la Torre V; Mestres J; Pastor M; Taboureau O; Rarey M; Chichester C; Pettifer S; Blomberg N; Harland L; Williams-Jones B; Ecker GF Drug Discov Today; 2013 Sep; 18(17-18):843-52. PubMed ID: 23702085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]